LabCorp wins FDA clearance for at-home COVID-19 test

LabPulse.com staff writers
Apr 20, 2020
2016 09 02 09 36 05 93 Fda Logo V2 400

LabCorp has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Pixel by LabCorp COVID-19 at-home test kit. The kit is the first to be approved by the FDA for self-collection of samples by patients at home.

The test kit can now be used by individuals to self-collect nasal swab specimens at home if recommended by a healthcare provider after completion of a COVID-19 questionnaire, according to LabCorp. Offered through the company's Pixel by LabCorp platform, the kits will initially be available to healthcare workers and first responders who may have been exposed to COVID-19 or may be symptomatic.

Consumers will be able to access the COVID-19 self-collection kits in the coming weeks, the vendor said.

Latest in FDA Clearance
Fda Button Social
Zymo Research, Ad Astra Diagnostics receive FDA 510(k) clearances
November 16, 2023
Fda Button Social
FDA grants approval to Takeda’s metastatic colorectal cancer therapy
November 9, 2023
Coronavirus Hologram Blue Social
3EO Health to launch FDA-approved COVID-19 test
October 20, 2023
Dna Cancer Cell Social
FDA authorizes Invitae hereditary cancer panel
October 5, 2023
Related Stories
2020 06 25 17 02 8042 Lab Corp Neutralizing Antibody Visual 400
Pathology, histology
Labcorp neutralizing antibody test could help screen recovered COVID-19 patients
2020 03 10 00 02 9515 Delivery Package Box 400
Accreditation
FDA authorizes home COVID-19 nasal sample kit
2020 05 15 15 00 8471 Lab Corp Finger Stick 400
Infectious
LabCorp gives employers a hand with screening staff for coronavirus
2020 05 13 21 56 3322 2020 05 13 Mail In Test 400
Infectious
Mail-in blood test created for vulnerable kids with organ transplants
More in FDA Clearance
Zymo Research, Ad Astra Diagnostics receive FDA 510(k) clearances
Molecular diagnostics firm Zymo Research and rapid diagnostics developer Ad Astra Diagnostics have both received 510(k) clearances from the U.S. Food and Drug Administration.
November 16, 2023
Fda Button Social
FDA grants approval to Takeda’s metastatic colorectal cancer therapy
The U.S. Food and Drug Administration (FDA) has approved a chemotherapy-free oral target therapy for patients who have been previously treated for metastatic colorectal cancer (mCRC).
November 9, 2023
Fda Button Social
3EO Health to launch FDA-approved COVID-19 test
Molecular diagnostics startup 3EO Health is preparing to launch a newly approved SARS-CoV-2 test with its portable molecular device, saying it will “expand access” to the technology.
October 20, 2023
Coronavirus Hologram Blue Social
FDA authorizes Invitae hereditary cancer panel
The U.S. Food and Drug Administration (FDA) has granted de novo authorization to an Invitae panel that tests for hundreds of genetic variants that indicate whether a person has a higher risk of developing certain cancers.
October 5, 2023
Dna Cancer Cell Social
ProciseDx receives FDA de novo authorization for therapeutic drug monitoring tests
ProciseDx has received U.S. Food and Drug Administrtion (FDA) de novo marketing authorization for its point-of-care tests for monitoring levels of infliximab and adalimumab in patients being treated for inflammatory bowel diseases.
October 5, 2023
Fda Button Social
Thermo Fisher receives FDA clearance for neuroendocrine tumor assay
Thermo Fisher has received clearance from the U.S. Food and Drug Administration (FDA) for its Brahms chromogranin A (CgA) II Kryptor test, a CgA immunoassay for assessing tumor progression in gastroenteropancreatic neuroendocrine tumor patients.
October 2, 2023
Fda Sign Dc Social
FDA starts one-year pilot program to tackle risks of lab developed oncology tests
The goal is to provide laboratories with information to support development of LDTs for specific cancer biomarkers, to facilitate “better and more consistent” testing and, by extension, “better drug selection and improved care for patients with cancer."
July 21, 2023
Fda Logo V2 Social
Roche receives FDA clearance for test to accelerate diagnosis of Alzheimer’s
The new 510(k) clearance covers two tests that run on Roche’s Elecsys immunoassay system. One of the assays, which measures beta-amyloid, was part of the 510(k) clearance that Roche received last year.
June 29, 2023
Alzheimers Phases Amyloid Social
FDA grants 510(k) clearance, CLIA waiver for BioFire multiplex respiratory panel
The FDA reviewed the BioFire test through a dual 510(k) and CLIA waiver pathway, which was designed to speed bringing accurate IVD tests to CLIA-waived settings.
February 7, 2023
Fda Button Social
FDA greenlights Precision BioLogic chromogenic assay to identify factor IX deficiency
The assay is intended for use by clinical labs to identify factor IX deficiency in human plasma and aid in the management of hemophilia B.
January 5, 2023
Fda Sign Dc Social
Roche nabs FDA clearance for two Alzheimer's disease CSF assays
The assays measure beta Amyloid (1-42) and Phospho Tau (181P) concentrations in cerebrospinal fluid samples from adults age 55 and older.
December 8, 2022
Alzheimers Phases Amyloid Social
HemoSonics obtains FDA clearance for whole-blood hemostasis system, cartridge for POC use
The system leverages medical-grade ultrasound technology to measure the coagulation properties of a whole blood sample.
November 30, 2022
Lab Blood Samples Social (1)
Page 1 of 6
Next Page